Glimepiride urethane | CAS# 119018-30-3 | Biochemical

MedKoo Cat#: 575899 | Name: Glimepiride urethane

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Glimepiride urethane is a third generation sulfonylurea compound, which increases the release of insulin from pancreatic beta cells. In addition, glimepiride increases the activity of intracellular insulin receptors. Glimepiride increases osteoblast proliferation and differentiation, which is thought to be related to its ability to activate the PI3K and Akt pathway. Furthermore, Glimepiride enhances intrinsic peroxisome proliferator-activated receptor γ activity. Glimepiride also increases protein expression of glucose transports 1 and 4, and is a potent KIR channel blocker.

Chemical Structure

Glimepiride urethane

CAS#119018-30-3 (urethane)

Theoretical Analysis

MedKoo Cat#: 575899

Name: Glimepiride urethane

CAS#: 119018-30-3 (urethane)

Chemical Formula: C18H23N3O6S

Exact Mass: 409.1308

Molecular Weight: 409.46

Elemental Analysis: C, 52.80; H, 5.66; N, 10.26; O, 23.44; S, 7.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

119018-29-0 (sulfonamide) 119018-30-3 (urethane) 93479-97-1

Synonym

Glimepiride urethane

IUPAC/Chemical Name

methyl ((4-(2-(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamido)ethyl)phenyl)sulfonyl)carbamate

InChi Key

UZDRZEOOIXNUTE-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H23N3O6S/c1-4-15-12(2)11-21(16(15)22)17(23)19-10-9-13-5-7-14(8-6-13)28(25,26)20-18(24)27-3/h5-8H,4,9-11H2,1-3H3,(H,19,23)(H,20,24)

SMILES Code

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)OC)C1=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 409.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Rizvi SM, Shaikh S, Naaz D, Shakil S, Ahmad A, Haneef M, Abuzenadah AM. Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer's Disease-Diabetes Dual Therapy. Neurochem Res. 2016 Feb 17. [Epub ahead of print] PubMed PMID: 26886763. 2: Osborne C, West E, Nolan W, McHale-Owen H, Williams A, Bate C. Glimepiride protects neurons against amyloid-β-induced synapse damage. Neuropharmacology. 2016 Feb;101:225-36. doi: 10.1016/j.neuropharm.2015.09.030. Epub 2015 Oct 8. PubMed PMID: 26432105. 3: Tani S, Nagao K, Hirayama A. Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study. Drug Res (Stuttg). 2016 Feb;66(2):94-9. doi: 10.1055/s-0035-1549993. Epub 2015 May 26. PubMed PMID: 26011816. 4: Dungan KM, Weitgasser R, Perez Manghi F, Pintilei E, Fahrbach JL, Jiang HH, Shell J, Robertson KE. A 24-week Study to Evaluate the Efficacy and Safety of Once Weekly Dulaglutide Added on to Glimepiride in Type 2 Diabetes (AWARD-8). Diabetes Obes Metab. 2016 Jan 22. doi: 10.1111/dom.12634. [Epub ahead of print] PubMed PMID: 26799540. 5: Reginald-Opara JN, Attama A, Ofokansi K, Umeyor C, Kenechukwu F. Molecular interaction between glimepiride and Soluplus(®)-PEG 4000 hybrid based solid dispersions: Characterisation and anti-diabetic studies. Int J Pharm. 2015 Dec 30;496(2):741-50. doi: 10.1016/j.ijpharm.2015.11.007. Epub 2015 Nov 12. PubMed PMID: 26581773. 6: Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care. 2015 Dec;38(12):2241-9. doi: 10.2337/dc14-1625. Epub 2015 Jun 18. PubMed PMID: 26089386. 7: Kousoulakou H, Kalogeropoulou M, Panitti E. Cost-Effectiveness Analysis of Vildagliptin vs. Glimepiride as Add-On to Metformin in the Management of Type 2 Diabetes Mellitus in Greece. Value Health. 2015 Nov;18(7):A608. doi: 10.1016/j.jval.2015.09.2101. Epub 2015 Oct 20. PubMed PMID: 26533416. 8: Ambery P, Stylianou A, Atkinson G, Dott C, Baylor Curtis L, Haque N, LaCroix K, Min KW; glimepiride/atorvastatin investigational team. Open-label randomized non-inferiority trial of a fixed-dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin. Diabet Med. 2015 Oct 20. doi: 10.1111/dme.13003. [Epub ahead of print] PubMed PMID: 26484794.